See more : ZJBC Information Technology Co., Ltd (000889.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Allurion Technologies Inc. (ALUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allurion Technologies Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Fluidra, S.A. (FDR.MC) Income Statement Analysis – Financial Results
- Willfar Information Technology Co., Ltd. (688100.SS) Income Statement Analysis – Financial Results
- TenX Keane Acquisition Ordinary Share (TENK) Income Statement Analysis – Financial Results
- PharmChem, Inc. (PCHM) Income Statement Analysis – Financial Results
- Mostostal Zabrze S.A. (MSZ.WA) Income Statement Analysis – Financial Results
Allurion Technologies Inc. (ALUR)
About Allurion Technologies Inc.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 53.47M | 64.21M | 38.24M | 0.00 |
Cost of Revenue | 11.97M | 13.49M | 9.05M | 0.00 |
Gross Profit | 41.50M | 50.73M | 29.19M | 0.00 |
Gross Profit Ratio | 77.61% | 79.00% | 76.33% | 0.00% |
Research & Development | 27.69M | 16.97M | 5.73M | 0.00 |
General & Administrative | 46.02M | 15.37M | 8.82M | 0.00 |
Selling & Marketing | 46.86M | 50.41M | 27.14M | 0.00 |
SG&A | 92.88M | 65.77M | 35.96M | 4.56K |
Other Expenses | 0.00 | -1.15M | -555.00K | -610.00 |
Operating Expenses | 120.58M | 82.74M | 41.69M | 5.17K |
Cost & Expenses | 132.55M | 96.22M | 50.74M | 5.17K |
Interest Income | 0.00 | 10.66M | 49.77K | 0.00 |
Interest Expense | 10.57M | 4.43M | 3.67M | 0.00 |
Depreciation & Amortization | 746.00K | 895.00K | 707.00K | 206.30K |
EBITDA | -69.03M | -32.28M | -12.35M | -5.17K |
EBITDA Ratio | -129.11% | -48.52% | -32.29% | 0.00% |
Operating Income | -79.08M | -32.01M | -12.50M | -5.17K |
Operating Income Ratio | -147.90% | -49.85% | -32.69% | 0.00% |
Total Other Income/Expenses | -1.27M | -5.59M | 115.00K | 1.00 |
Income Before Tax | -80.34M | -37.60M | -12.39M | -5.17K |
Income Before Tax Ratio | -150.27% | -58.56% | -32.39% | 0.00% |
Income Tax Expense | 264.00K | 143.00K | 3.11M | -206.30K |
Net Income | -82.30M | -37.74M | -12.39M | -5.17K |
Net Income Ratio | -153.93% | -58.78% | -32.39% | 0.00% |
EPS | -2.31 | -1.40 | -0.11 | 0.00 |
EPS Diluted | -2.31 | -1.40 | -0.11 | 0.00 |
Weighted Avg Shares Out | 35.58M | 26.92M | 107.81M | 107.81M |
Weighted Avg Shares Out (Dil) | 35.58M | 26.92M | 107.81M | 107.81M |
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
Source: https://incomestatements.info
Category: Stock Reports